Kornimate/medical-research-clean huggingface dataset:
comparison of endoscopic lumbar decompression and minimally invasive transforaminal lumbar interbody fusion(mis-tlif) for degenerative lumbar spondylolisthesis

Conditions: Degenerative Lumbar Spondylolisthesis; Lumbar Degenerative Disease; Lumbar Spinal Stenosis

Summary: comparing the functional and radiographic outcomes in surgical treatment in failed conservative treatment, single-level low grade degenerative lumbar spondylolisthesis between minimal invasive surgery transforaminal lumbar interbody fusion, which is conventional treatment recently, and endoscopic lumbar decompression, which is minimal invasive in symptomatic treatment.

this was a randomized controlled trial in patient with single-level low grade degenerative lumbar spondylolisthesis with failed conservatives treatment, by comparing two group of surgical intervention between minimally invasive transforaminal lumbar interbody fusion (mis tlif) and endoscopic lumbar decompression using functional outcomes. the participants were randomized into two groups with 33 cases each group (total = 66) by using computer generated program with block of four randomization with allocation ratio 1:1. the control group received conventional treatment which is minimal invasive surgery transforaminal lumbar interbody fusion while the experimental group received endoscopic lumbar decompression. using odi score as primary outcome. data were analyzed using chi-square test for categorical data (eg, sex, symptoms of weakness and numbness, level of spondylolisthesis) and unpaired t-test for continuous data (eg. vas score, odi, slippage percentage, lumbar lordosis degree, slip angle, op time) which considered significant difference of the outcomes when p \< 0.05 with a power of 80%. consider endoscopic decompression is non-inferiority to mis-tlif when upper limit of the one-sided 95%ci for the differences in odi means is less than margin (12.8 points) if the results show that endoscopic decompression is non-inferiority to mis tlif, endoscopic lumbar decompression may be a choice of treatments giving benefit of minimal invasive surgery and avoid interbody fusion complication such as pseudoarthrosis, adjacent problems and operative blood loss

Eligibility criteria:
inclusion criteria: * single level lumbar degenerative spondylolisthesis (meyerding grading grade i or ii). * failed conservative treatment for at least 3 months. * no instability evidence of levels of lesion (consideration from translation more than 5 mm or angulation change more than 10 degree in flexion and extension l-s plain films ). * able to follow up for at least 12 months. * patient who vorantarily agree to participate in research. exclusion criteria: * patients with severe foraminal stenosis diagnosed by mri. * patients who have previously undergone lumbar spine surgery (revision surgery). * patients with other abnormalities in the lumbar spine, such as infection, tumors, or fractures. * patients who cannot undergo surgery due to underlying conditions or who cannot maintain the prone position for extended periods.
psychological evaluation after scs implantation

Conditions: Psychological Disability; Cognitive Impairment; Quality of Life

Summary: spinal cord stimulation (scs) is a therapeutic option for patients with chronic low back pain (clbp) syndrome, when pharmacological, psychological, physical and occupational therapies or surgery fail to reduce symptoms. clbp is a common disease with several negative consequences on the quality of life, work and activity ability and increased costs to the health-care system. we have therefore designed this observational study to assess global cognitive functioning in three different groups of patients: patients with chronic pain undergoing intervention (experimental group), patients with chronic pain following traditional therapies (comparison group) and healthy participants matched for age and schooling (healthy subjects). a neuropsychological assessment battery designed to assess global cognitive functioning, behavioral symptomatology, metacognition, quality of life, interoception, pain perception, self-efficacy, and coping styles will be conducted.


Eligibility criteria:
inclusion criteria: * age greater than 18 years * presence of chronic pain treated with spinal cord stimulation (experimental group) * presence of chronic pain receiving standard therapies (comparison group) * healthy participants matched for age and schooling (control group). exclusion criteria: * consent denied

Keywords: spinal cord stimulation psychological disability cognitive impairment quality of life metacognition pain and disability
use of emg to assess clinical hypertonia

Conditions: Cerebral Palsy; Hypertonia; Spasticity; Dystonia; Rigidity

Summary: a handheld surface electromyography device will be tested by clinicians on children with limb hypertonia, and inter-rater reliability will be assessed with and without the device.

hypothesis: qualitative surface emg measurement during passive movement will increase the inter-rater reliability of clinicians for diagnosis of spasticity and dystonia in children with hypertonia. specific aims: 1. develop a handheld surface emg device with auditory output that can be used similarly to a stethoscope to listen non-invasively to the activity of muscles. 2. provide clinicians at 5 different institutions with a device to test for 2 months in their own clinics. 3. bring all 5 clinicians to stanford university for a single-day exercise in which each clinician will examine 10 children with hypertonia. each clinician will rate the children without using the device, and then again with the device. intra-class correlations and kappa statistics will be used to assess whether the use of the device leads to improved inter-rater reliability.

Eligibility criteria:
inclusion criteria: * age 6-18 * hypertonia in at least one limb due to spasticity exclusion criteria: * any condition that would increase the risk of participation

Keywords: hypertonia childhood
iron homoeostasis in inflammation

Conditions: Inflammation; Bacterial Infections and Mycoses; Anemia, Iron-Deficiency; Iron Overload

Summary: the purpose of this study is to survey iron storage levels and their prognostic consequences in the context of acute inflammation. the impact of iron substitution in inflammatory states is controversial. we hypothesize that iron substitution may influence outcome in patients in inflammatory states.

* background: iron deficiency is frequently encountered in the elderly, after bleeding and in the context of neoplasia. our 2013 pilot study showed that iron deficiency is a common problem in medical inpatients (13.7%) and that about 55% of these also showed signs of inflammation. the relevance of iron storage levels on clinical outcome in the presence of inflammation is conflicting. on the one hand, lack of iron prevents many viruses and bacteria, as well as other microorganisms, to reproduce and on the other hand the abundance of available iron stimulates hematopoiesis and reduces symptoms of iron deficiency. * methodology: we plan to enroll 1000-1500 patients with laboratory signs of inflammation during a period of six months and to analyze iron specific laboratory parameters twice during hospital stay. additional laboratory analyses are planned for a smaller sample to portray the processes in iron homeostasis during inflammation. * significance: contradicting evidence of forty and more years of scientific research backs current therapeutic practices in patients with inflammatory disease and iron deficiency. this study records prevalence of different iron storage states, mortality, morbidity and therapies in inflammatory states combined with iron deficiency and could very well be able to recommend a therapeutic regimen as well as limits for typically used laboratory parameters.

Eligibility criteria:
inclusion criteria: * age: ≥18 * hospitalized patient in internal medicine (≥ 24h) * evidence of an inflammatory state, determined as a c reactive protein (crp) value \>5 mg/l * written informed consent exclusion criteria: * history of terminal renal insufficiency in terms of dialysis or use of erythropoiesis-stimulating agents * pregnancy * history of allogeneic stem cell transplantation

Keywords: hepcidins homeostasis iron/administration & dosage biological markers/blood
comparative study between different approaches to cpa-petroclival meningiomas

Conditions: Brain Neoplasms

Summary: • give an effective treatment for cpa-petroclival meningiomas and can detect the best approach for these tumors. . improve the outcome of these patients and decease rate of recurrence.

there are several lesions arising in the petroclival region. the most frequent tumor is the petroclival meningioma, followed by chondrosarcomas, chordomas, schwannomas of the cranial nerves v and vii, and other malignant tumors \[1, 2, 3, 4, 5\]. petroclival meningiomas are tumors of the skull base that present a formidable challenge to surgical resection because of their deep location and relationship to vital neurovascular structures. in the majority of the cases they are benign tumors, but may involve or infiltrate the skull base bone, the dura mater, the brainstem, and all important neurovascular structures of this region. the petroclival region comprises the anatomical location of the body of the sphenoid bone, the anterior central portion of the occipital bone, and is bordered on the lateral aspect by the petrous apex. the roof of this space is formed by the petroclival ligaments and the tentorium. this space contains important neurovascular structures that are frequently involved or displaced by the tumor in a variable pattern. the basilar artery with its branches may be embedded or displaced by the meningioma. the petrosal vein is often displaced posteriorly by the tumor. cranial nerves iii and iv are usually displaced upwardly and the nerve vi is often surrounded by tumor. petroclival meningiomas have their origin medial to cranial nerves v, vii, viii, ix, x, and xi, and reach the tentorium . they frequently extend to the middle cranial fossa, cavernous sinus, prepontine space, and down to the foramen magnum. these tumors frequently compress the brainstem making total removal very difficult or impossible without neurologic deficits. cerebellopontine angle (cpa) and low clivus meningiomas may reach these areas. these lesions usually need different surgical approaches as transpetrosal approach ( anterior, modified and combined ) and retrosigmoid approach

Eligibility criteria:
inclusion criteria: * patient with a single lesion . * patient with a denovo lesion. exclusion criteria: * patient with recurrent lesions. * patient with lesions after adjuvant therapy.
automated device for asthma monitoring and management in monitoring adults with lung cancer undergoing radiation therapy

Conditions: Lung Carcinoma

Summary: this pilot early phase i trial studies the automated device for asthma monitoring and management in monitoring adult patients with lung cancer who are undergoing radiation therapy. the automated device for asthma monitoring and management may provide useful information to doctors to help monitor adult patients with lung cancer and diagnose certain conditions earlier than traditional means.

primary objectives: i. determine compliance with the automated device for asthma monitoring and management (adamm) device in patients receiving radiation therapy (rt) for lung cancer. secondary objectives: i. evaluate feasibility of recruitment, acceptability of the adamm device, and compliance with electronic patient-reported outcomes (epros) in this patient population

Eligibility criteria:
inclusion criteria: * patients are capable of giving informed consent * patients are eligible to be treated with rt and plan to start treatment * patients have either metastatic or non-metastatic lung cancer as defined in history and physical * patients must be able to read or speak english * women of reproductive potential should have a negative serum or urine pregnancy test within one week prior to radiation planning ct scan exclusion criteria: * patients who cannot read or speak english * patients who are not candidates for rt treatment * women of childbearing potential who are pregnant or breastfeeding
a study of cellcept (mycophenolate mofetil) in combination therapy in heart transplant patients.

Conditions: Heart Transplantation

Summary: this study will investigate the efficacy and safety of cellcept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine a (trough level 150-200ng/ml) and steroids, in patients receiving a heart transplant. the anticipated time on study treatment is 24 weeks.


Eligibility criteria:
inclusion criteria: * adult patients, \>=18 years of age; * patients receiving their first heart transplant (single organ transplant). exclusion criteria: * patients with a positive donor-specific cross-match at the time of transplantation; * patients with any antibody-treated acute rejection; * known contraindications to treatment with sirolimus; * history of malignancy, other than excised non-melanoma skin cancer which has not recurred for 2 years.
lidocaine infusion for pain relief in children scheduled for tonsillectomy and adenoidectomy

Conditions: Children, Only; Tonsillar Hypertrophy; Adenoid Hypertrophy

Summary: lidocaine is widely available and is a very commonly used local anesthetic. when administered intravenously, lidocaine infusions have anti-inflammatory effects and have significantly decreased the reliance on opioid use for adequate pain management in adult abdominal and spine surgeries. a major advantage of lidocaine infusion is that it is not associated with a significant side effect profile.the role of lidocaine in pediatric acute perioperative pain remains limited.

the aim of the study is to determine if using lidocaine continuously during anesthesia care will decrease post-operative pain for children having their tonsils and adenoids removed.

Eligibility criteria:
inclusion criteria: - scheduled tonsillectomy and adenoidectomy with or without myringotomy/pe tubes at hasbro children's hospital exclusion criteria: * history of allergies to local anesthetics * physical or developmental delays * psychiatric illness * current use of sedative or anticonvulsive medications * use of premedication (oral/nasal) * pre-existing cardiovascular, renal, or hepatic disease * pre-existing cerebral or neuromuscular disease * patient with personal or family history of malignant hyperthermia * recent history of upper respiratory infection within last 7 days * regular use of analgesic medications

Keywords: lidocaine tonsillectomy and adenoidectomy pain
non-myeloablative allogeneic transplantation from unrelated donors in multiple myeloma

Conditions: Multiple Myeloma

Summary: the protocol aims at reducing transplant toxicity and mortality in patients with multiple myeloma.

primary end points are engraftment and non-relapse mortality. secondary end points are disease response, overall survival, progression and event free survivals. patient eligibility criteria. inclusion criteria included: * diagnosis of durie-salmon stage iia-iiib multiple myeloma * age \> 18 and ≤ 65 years at the start of the donor search * presence of concurrent co-morbidities precluding myeloablative conditioning or refusal to undergo a conventional allogeneic transplant * capacity to give informed consent exclusion criteria included: * age \> 65 years * karnofsky performance status score \< 60% * progressive disease or stable disease for less than three months * central nervous system (cns) involvement * left ventricular ejection fraction \< 35% or symptomatic heart failure * poorly controlled hypertension * pulmonary dysfunction with diffusing capacity for carbon monoxide (dlco) \< 40% and/or need for continuous oxygen supplementation * abnormal liver disease with a serum bilirubin greater than twice normal or sgot and/or sgpt greater than four times the upper limits of normal * hiv positive patients * pregnancy * refusal to use contraceptive techniques during and for 12 months following treatment informed consent is obtained during study registration from each patient according to the institutional review boards of the participating centers. the study is conducted according to the declaration of helsinki.

Eligibility criteria:
inclusion criteria: * diagnosis of durie-salmon stage iia-iiib multiple myeloma * age \> 18 and ≤ 65 years at the start of the donor search * presence of concurrent co-morbidities precluding myeloablative conditioning or refusal to undergo a conventional allogeneic transplant * capacity to give informed consent exclusion criteria: * age \> 65 years * karnofsky performance status score \< 60% * progressive disease or stable disease for less than three months * central nervous system involvement * left ventricular ejection fraction \< 35% or symptomatic heart failure * poorly controlled hypertension * pulmonary dysfunction with diffusing capacity for carbon monoxide (dlco) \< 40% and/or need for continuous oxygen supplementation * abnormal liver disease with a serum bilirubin greater than twice normal or sgot and/or sgpt greater than four times the upper limits of normal * hiv positive patients * pregnancy * refusal to use contraceptive techniques during and for 12 months following treatment
concurrent chemoradiotherapy containing paclitaxel&cisplatin with/without tarceva in locally advanced esophageal cancer

Conditions: Esophageal Cancer

Summary: this study is multi-center randomized phase iii one to evaluate the difference in local-control and survival rate between patients receiving concurrent chemoradiotherapy combined tarceva or not.

for the esophageal carcinoma in ii\~iii stage, routine dosage of paclitaxel and platinum medicine chemotherapy concurrently radical radiotherapy is worthy to be studied. on this base, we advanced approach the enlarged field radiotherapy and the intervention of tarceva. and we approach the therapeutic effect for this method theoretically, which may give a further reasonable guidance for the clinical therapy.

Eligibility criteria:
inclusion criteria: 1. subjects must be confirmed esophageal carcinoma pathologically 2. (eus)i～iva, without contraindication for radical radiotherapy 3. subjects haven't been given neither radiotherapy nor chemotherapy before 4. age 18-70,behavioral status evaluation ecog scores 0-2 and anticipated survival more than 6 months 5. in 7 days after being selected, subjects should follow the status: wbc ≥ 4.0 x 10\^9/l; anc ≥ 1.5x 10\^9/l; plt ≥ 100 x 10\^9/l; hb ≥ 90 g/l; serum cr ≤ uln; serum bilirubin ≤ 1.5 uln; alt/ast ≤ 1.5 uln 6. subjects should sign for the informed consent 7. subjects should perform good compliance 8. male and female subjects who have the ability of fertility should take contraception during the whole course and also 3 months after last dosage.in 7 days before the inclusion, urine pregnancy tests of subjects should be negative. exclusion criteria: 1. patients who have or are currently undergoing additional chemotherapy, radiation therapy or targeted therapy 2. complete obstruction of the esophagus, or patients who have the potential to develop perforation 3. patients with a history of malignancy (except that skin carcinomas or in situ breast cancer, oral cancer and cervical cancer with expected survival ≥2 years 4. patients who multiple foci esophagus 5. patients who are/were given any other medicine tests currently/in last 4 weeks 6. experienced hypersensitiveness with similar medicine or other kinds of bio-medicines 7. women in status of pregnancy 8. patients who have complications exist as following: (1)uncontrolled angina and heart failure, have a history of hospitalization in 3 months; (2)a history of myocardial infarction in the past 6 months; (3)there is a need for antibiotic treatment of acute bacterial or fungal infection; (4)chronic obstructive pulmonary disease, or other lung disease requiring hospitalization; (5)drug addiction, alcoholism and aids disease or long-term virus carriers; (6)uncontrollable seizures, or loss of insight because of mental illness

Keywords: esophageal cancer chemoradiation radiosensitivity egfr inhibition
efficacy of drug-eluting vertebral artery stenting treatment for atherosclerotic vertebral arteries stenosis

Conditions: Ischemic Stroke; Vertebral Artery Stenosis

Summary: this is a prospective, multi-center, open-access, single-arm trial to observe the real-world clinical efficacy of drug-eluting vertebral artery stenting system treatment for atherosclerotic vertebral arteries stenosis. patients will be followed at 30 days, 6, and 12 months post-procedure and annually for 1 year within 3 years.

stroke has been one of the most important causes of disability and death worldwide today. ischemic stroke accounts for more than 50% of these strokes. the results of epidemiological surveys show that in 2018, more than 3 million new strokes occurred each year in china. in 2018, more than 3 million people suffered from a stroke, and more than 2 million people died from a stroke. studies show that about 25% to 40% of transient ischemic attacks (tia) or strokes occur in the posterior circulation. the subclavian and vertebral arteries are important blood vessels in the posterior circulation and are important original sites for ischemic strokes in the posterior circulation. about 20% of strokes in the posterior circulation are caused by extracranial vertebral artery stenosis (ecvas). endovascular intervention is the recommended treatment for ecvas. it is effective in promoting the perfusion of brain tissue in the area of the responsible artery, thereby reducing the risk of stroke recurrence, improving neurological prognosis, and reducing symptoms. the drug-eluting stent is effective in reducing the incidence of postoperative restenosis (isr), thus further reducing the long-term risk of stroke. vertebral artery drug-eluting stents maurora® was approved for marketing in 2020 and has been shown to be effective in reducing restenosis in clinical trials. the purpose of this study is to further investigate its long-term effectiveness in treating vertebral artery stenosis in the real world.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old, gender is not limited; 2. patients with medically prescribed rapamycin drug-eluting vertebral artery stent systems; 3. patients and family members fully understand the trial's purpose, voluntarily participate in the trial and sign the informed consent form. exclusion criteria: 1. unable to receive dual antiplatelet therapy due to known disease, or severe coagulation abnormalities, severe infections that are not controlled, severe systemic disease, uncontrollable hypertension, and contraindicated for surgery; 2. with an aneurysm that cannot be treated earlier or simultaneously or is not suitable for surgery; 3. gastrointestinal disease with active bleeding; 4. previous myocardial infarction or large-scale cerebral infarction within 2 weeks; 5. known contraindications to heparin, rapamycin, anesthesia, and contrast agents; 6. life expectancy less than 12 months; 7. the investigator judged patients to be unsuitable for participation in this study.